FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

137 letters match. Newest first.

  1. Nanjing Hanxin Pharmaceutical Technology Co. Ltd.

    FDA warns Nanjing Hanxin of drug-ingredient quality failures and poor supplier oversight; its drugs face U.S. import detention.

    High risk
  2. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  3. Tianjin Healthcare Medical Technology Co., Ltd.

    Chinese API maker refused FDA records requests, and all its drugs now face a US import alert.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  5. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  6. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  7. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  8. Royal Peptides LLC

    FDA warned Royal Peptides LLC that seven peptide products sold on its website are unapproved new drugs.

    High risk
  9. TXP Innovations LLC dba Tex Peptides

    FDA warned Dallas peptide seller TXP Innovations (Tex Peptides) that its website sells unapproved injectable drugs, including semaglutide and tirzepatide.

    High risk
  10. Shoolin Pharma Chem LLP

    Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.

    High risk
  11. PReye, LLC

    FDA warned PReye, LLC that its unapproved eye drop PReye Vitamin SEE was made without sterile controls in an unclassified office.

    High risk
  12. Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd.

    Tianjin Kilo Pharmaceutical Sci-tech, a drug ingredient maker, cited for quality failures and missing listings for demecarium bromide and chlorambucil.

    High risk
  13. Shimoga Chemicals

    FDA warns Shimoga Chemicals of manufacturing quality and data integrity failures in clomiphene citrate active ingredient.

    High risk
  14. Extra Medication / www.extramedication.com

    FDA warned website Extra Medication for selling unapproved, misbranded ketamine drugs to U.S. consumers without prescriptions.

    High risk
  15. Pure Arylcyclohexylamine Store / www.arylcyclohexylamine.com

    FDA warned Pure Arylcyclohexylamine Store it sells unapproved, misbranded ketamine drugs, including an injectable, to U.S. consumers online.

    High risk
  16. Ketamine Troche Store / www.ketaminetrochestore.com

    FDA warned online seller Ketamine Troche Store that its website sells unapproved, misbranded ketamine drugs without prescriptions.

    High risk
  17. Ketamine Store / www.ketaminestore.org

    FDA warned website Ketamine Store for selling unapproved, misbranded ketamine liquid and compounded products online without prescriptions.

    High risk
  18. Legit Ketamine Suppliers / www.legitketaminesuppliers.com

    FDA warns Legit Ketamine Suppliers website for selling unapproved, misbranded ketamine and esketamine drugs to U.S. consumers.

    High risk
  19. Ketdaxandrugs / www.ketdaxandrugs.org

    FDA warned Ketdaxandrugs it sells unapproved, misbranded ketamine "KETAMINE CRYSTAL" online without prescriptions to U.S. consumers.

    High risk
  20. ketaminetroches.com

    FDA warns ketaminetroches.com that it sells unapproved and misbranded ketamine troches to U.S. consumers online.

    High risk
  21. Keta Med Lab / www.ketamedlab.com

    Keta Med Lab's website sold unapproved, misbranded ketamine liquid, troches and nasal spray to U.S. consumers without prescriptions, FDA says.

    High risk
  22. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  23. NativeMed LLC dba NativeMed

    FDA warned telehealth seller NativeMed that its website misbranded compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  24. HydraMed IV LLC dba HydraMed

    FDA told Denver telehealth seller HydraMed its website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  25. Nexus Health Solutions LLC dba Harper Meds

    FDA warned telehealth seller Harper Meds that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Low
  26. FitRX, LLC dba AM RX

    FDA warned telehealth seller AM RX that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  27. Altru Telehealth, LLC dba Altru Telehealth

    FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.

    Low
  28. Eden Health International Inc. dba Eden

    FDA warned Eden Health International that its telehealth website misbrands compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  29. Trinity HealthCare Supply, LLC dba altRx

    FDA warns altRx over misleading website claims for compounded semaglutide and tirzepatide, including 'clinically proven' and wrong compounder label.

    Low
  30. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  31. Thrivelab Co. dba Thrivelab

    FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.

    Medium
  32. VivioMD Group LLC dba VivioMD

    FDA warned VivioMD that its website misbrands compounded semaglutide and tirzepatide by implying VivioMD is the compounder.

    Low
  33. Glow Medispa, LLC dba Mint Med

    FDA warns telehealth seller Mint Med that its website labels falsely suggest it compounds the semaglutide and tirzepatide drugs it sells.

    Low
  34. Public Health Solution LLC dba DrMedHealth

    FDA warned DrMedHealth over false website claims that compounded semaglutide and tirzepatide have the same active ingredient as Ozempic and Mounjaro.

    Low
  35. D&H Medical Services

    FDA warned D&H Medical Services that its website falsely suggests its compounded semaglutide and tirzepatide are the same as FDA-approved brand drugs.

    Low
  36. Momentum Health 360 dba Momentum Health

    FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.

    Low
  37. Medica Weight Loss

    FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.

    Medium
  38. Ezra Holdco LLC dba Ezra

    FDA says Ezra's website misbrands compounded semaglutide and tirzepatide by labeling them as Ezra-made when they are not.

    Low
  39. Ready Med

    FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.

    Low
  40. FITISH

    FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.

    Low
  41. OrderlyMeds LLC dba OrderlyMeds

    FDA warned OrderlyMeds over website claims for compounded semaglutide and tirzepatide, saying its labels and 'FDA-licensed pharmacy' claim are misleading.

    Low
  42. Roen Health, Inc. dba RoenRx

    FDA warned RoenRx that its website misbrands compounded semaglutide with misleading approval claims and a company label implying it makes the drug.

    Medium
  43. Joi and Blokes dba Joi + Blokes

    FDA warned telehealth seller Joi + Blokes that its website misbrands compounded semaglutide and tirzepatide with false, misleading claims.

    Medium
  44. Nova Vascular LLC dba NOVARX

    FDA warned NOVARX over false website claims that compounded semaglutide and tirzepatide products are FDA-approved or from FDA-approved pharmacies.

    Low
  45. Clover Meds LLC dba Clover Meds

    Clover Meds, a telehealth seller, misbranded compounded semaglutide and tirzepatide with false website claims that it makes the drugs and uses 'FDA-licensed' facilities.

    Medium
  46. Maximus Health, Inc. dba Maximus

    FDA warned Maximus Health that its website makes false or misleading claims about compounded semaglutide and tirzepatide.

    Low
  47. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  48. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  49. Hangzhou Yiqi Biotechnology Co., Ltd

    FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.

    High risk
  50. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk